Immunomodulation by mucosal gene transfer using TGF-beta DNA.
AUTOR(ES)
Kuklin, N A
RESUMO
This report evaluates the efficacy of DNA encoding TGF-beta administered mucosally to suppress immunity and modulate the immunoinflammatory response to herpes simplex virus (HSV) infection. A single intranasal administration of an eukaryotic expression vector encoding TGF-beta1 led to expression in the lung and lymphoid tissue. T cell-mediated immune responses to HSV infection were suppressed with this effect persisting as measured by the delayed-type hypersensitivity reaction for at least 7 wk. Treated animals were more susceptible to systemic infection with HSV. Multiple prophylactic mucosal administrations of TGF-beta DNA also suppressed the severity of ocular lesions caused by HSV infection, although no effects on this immunoinflammatory response were evident after therapeutic treatment with TGF-beta DNA. Our results demonstrate that the direct mucosal gene transfer of immunomodulatory cytokines provides a convenient means of modulating immunity and influencing the expression of inflammatory disorders.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=508903Documentos Relacionados
- Colon cancer cells that are not growth inhibited by TGF-beta lack functional type I and type II TGF-beta receptors.
- A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1.
- Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA.
- Reconstitution and transphosphorylation of TGF-beta receptor complexes.
- Phosphorylation of Ser165 in TGF-beta type I receptor modulates TGF-beta1-induced cellular responses.
